C Ryan Miller
Overview
Explore the profile of C Ryan Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
9315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bajpai P, Agarwal S, Afaq F, Al Diffalha S, Chandrashekar D, Kim H, et al.
J Exp Clin Cancer Res
. 2024 Jul;
43(1):192.
PMID: 38992681
Background: Treatment with regorafenib, a multiple-kinase inhibitor, to manage metastatic colorectal cancers (mCRCs) shows a modest improvement in overall survival but is associated with severe toxicities. Thus, to reduce regorafenib-induced...
2.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby G, et al.
Nat Commun
. 2024 Mar;
15(1):1957.
PMID: 38438348
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM...
3.
Miller C, Hjelmeland A
J Clin Invest
. 2023 Nov;
133(22).
PMID: 37966120
Glioblastoma (GBM) tumor-associated macrophages (TAMs) provide a major immune cell population contributing to growth and immunosuppression via the production of proinflammatory factors, including IL-1. In this issue of the JCI,...
4.
Merati A, Kotian S, Acton A, Placzek W, Smithberger E, Shelton A, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37761989
Glioblastoma (GBM) remains an incurable disease with an extremely high five-year recurrence rate. We studied apoptosis in glioma stem cells (GSCs) in response to HDAC inhibition (HDACi) combined with MEK1/2...
5.
Bredel M, Espinosa L, Kim H, Scholtens D, McElroy J, Rajbhandari R, et al.
Cell Rep Med
. 2023 Jun;
4(6):101082.
PMID: 37343523
Genetic alterations help predict the clinical behavior of diffuse gliomas, but some variability remains uncorrelated. Here, we demonstrate that haploinsufficient deletions of chromatin-bound tumor suppressor NFKB inhibitor alpha (NFKBIA) display...
6.
Bell M, Ouyang X, Shelton A, Huynh N, Mueller T, Chacko B, et al.
J Neurochem
. 2023 May;
165(5):682-700.
PMID: 37129420
Enhancing protein O-GlcNAcylation by pharmacological inhibition of the enzyme O-GlcNAcase (OGA), which removes the O-GlcNAc modification from proteins, has been explored in mouse models of amyloid-beta and tau pathology. However,...
7.
Kesarwani P, Kant S, Zhao Y, Prabhu A, Buelow K, Miller C, et al.
Nat Commun
. 2023 Mar;
14(1):1459.
PMID: 36927729
There has been considerable scientific effort dedicated to understanding the biologic consequence and therapeutic implications of aberrant tryptophan metabolism in brain tumors and neurodegenerative diseases. A majority of this work...
8.
Skinner K, Koga T, Miki S, Gruener R, Grigore F, Torii E, et al.
bioRxiv
. 2023 Mar;
PMID: 36865329
Diffuse midline glioma (DMG) is a leading cause of brain tumor death in children. In addition to hallmark H3.3K27M mutations, significant subsets also harbor alterations of other genes, such as...
9.
Kesarwani P, Kant S, Zhao Y, Miller C, Chinnaiyan P
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428642
Glioblastoma (GBM) represents an aggressive and immune-resistant cancer. Preclinical investigations have identified anti-tumor activity of a ketogenic diet (KD) potentially being used to target GBM's glycolytic phenotype. Since immune cells...
10.
Lin B, Ziebro J, Smithberger E, Skinner K, Zhao E, Cloughesy T, et al.
Neuro Oncol
. 2022 Nov;
25(1):213.
PMID: 36416495
No abstract available.